Telitacicept
| Clinical data | |
|---|---|
| Trade names | Tai'ai |
| Other names | RC18 |
| Routes of administration | Injection |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE).[1] It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases.[2] In 2021, telitacicept was approved in China for the treatment of patients with active SLE.[3] It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS).[3]
Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).[3]
References[edit]
- ^ Fan Y, Gao D, Zhang Z (January 2022). "Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus". Drugs of Today. 58 (1): 23–32. doi:10.1358/dot.2022.58.1.3352743. PMID 35107091. S2CID 246405604.
- ^ Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y (December 2021). "Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease". Immunopharmacology and Immunotoxicology. 43 (6): 666–673. doi:10.1080/08923973.2021.1973493. PMID 34519594. S2CID 237504252.
- ^ a b c Dhillon S (September 2021). "Telitacicept: First Approval". Drugs. 81 (14): 1671–1675. doi:10.1007/s40265-021-01591-1. PMID 34463932. S2CID 237357826.